Skip to main content
Publications
Michaud K, Pope J, van de Laar M, Curtis JR, Kannowski C, Mitchell S, Bell J, Workman J, Paik J, Cardoso A, Taylor PC. A systematic literature review of residual symptoms and unmet need in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-16. doi: 10.1002/acr.24369
Lopez-Vicente M, Ribas Fito N, Vilor-Tejedor N, Garcia-Esteban R, Fernandez-Barres S, Dadvand P, Murcia M, Rebagliato M, Ibarluzea J, Lertxundi A, Fernandez-Somoano A, Tardon A, Lopez-Sabater MC, Romaguera D, Vrijheid M, Sunyer J, Julvez J. Prenatal omega-6:omega-3 ratio and attention deficit and hyperactivity disorder symptoms. J Pediatr. 2019 Jun;209:204-211.e. doi: 10.1016/j.jpeds.2019.02.022
Fernandez-Barres S, Vrijheid M, Manzano-Salgado CB, Valvi D, Martinez D, Iniguez C, Jimenez-Zabala A, Riano-Galan I, Navarrete-Munoz EM, Santa-Marina L, Tardon A, Vioque J, Arija V, Sunyer J, Romaguera D, Infancia y Medio Ambiente (INMA) Project. The association of Mediterranean Diet during pregnancy with longitudinal body mass index trajectories and cardiometabolic risk in early childhood. J Pediatr. 2019 Mar;206:119-27. doi: 10.1016/j.jpeds.2018.10.005
Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537
Lopez-Vicente M, Garcia-Aymerich J, Torrent-Pallicer J, Forns J, Ibarluzea J, Lertxundi N, Gonzalez L, Valera-Gran D, Torrent M, Dadvand P, Vrijheid M, Sunver J. Are early physical activity and sedentary behaviors related to working memory at 7 and 14 years of age? J Pediatr. 2017 Sep;188:35-41.e1. doi: 10.1016/j.jpeds.2017.05.079.
MacDougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089